3011029-58-3
Chemical Structure
XL01126
- CAS No.: 3011029-58-3
- Formula:C50H64ClFN10O6S2
- Molecular Weight:1019.69
IUPAC Name: 4-bromo-2-(dimethoxymethyl)pyridine
InChIKey: HKSBXNVKPFTBIG-SHFRUIRLSA-N
SMILES: O=C([C@H]1N(C([C@@H](NC(C2(F)CC2)=O)C(C)(SC[C@@H]3CC[C@@H](CN4CCN(C(C5=CC=C(NC6=NC=C(Cl)C(NC)=N6)C(OC)=C5)=O)CC4)CC3)C)=O)C[C@H](O)C1)NCC7=CC=C(C8=C(C)N=CS8)C=C7
Biological Activity: XL01126 is a blood-brain barrier-permeable, selective LRRK2 PROTAC degrader (DC50: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)). XL01126 forms a positively cooperative ternary complex with VHL E3 ubiquitin ligase and LRRK2, mediating the polyubiquitination and proteasomal degradation of LRRK2. XL01126 induces Mitophagy. XL01126 is applicable to research related to Parkinson's disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
XL01126 | 98.90% | XL01126 is a blood-brain barrier-permeable, selective LRRK2 PROTAC degrader (DC50: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)). XL01126 forms a positively cooperative ternary complex with VHL E3 ubiquitin ligase and LRRK2, mediating the polyubiquitination and proteasomal degradation of LRRK2. XL01126 induces Mitophagy. XL01126 is applicable to research related to Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Liu X, et al. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. Journal of the American Chemical Society. 2022 Sep 21;144(37):16930-16952. [Content Brief]
- [2]. Tang X, et al. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease. Journal of medicinal chemistry. 2023 Feb 23;66(4):2282-2307. [Content Brief]
- [3]. Li M, et al. Advancing Strategies for Proteolysis-Targeting Chimera Design. Journal of medicinal chemistry. 2023 Feb 23;66(4):2308-2329. [Content Brief]
Keywords
